LEO Pharma Announces Positive Topline 32-Week Key Results in ADHAND Trial (The AI Journal) - Nov 17, 2025 - "The trial met all key primary and secondary endpoints at Week 16 as well as all endpoints at Week 32, including efficacy on extent and severity of disease, itch, pain, sleep, and health-related quality of life and the safety and tolerability of continued tralokinumab treatment...At Week 16, tralokinumab also achieved a statistically significant reduction in both itch and pain versus placebo..."
P3 data • Atopic Dermatitis
|